PDX’s business intelligence platform renamed Explore Dx
PDX has renamed its Explore Rx business intelligence platform. The Fort Worth, Texas-based company’s data transparency and reporting software is now Explore Dx, which the company said was aimed at reflecting the platform’s ability to meet the business intelligence needs of the broader healthcare marketplace, as well as the needs of pharmacies.
“Subsequent to the rapid adoption of Explore Rx, we’re excited about this transition from providing innovative, pharmacy-specific solutions to now providing cutting-edge technology solutions that are relevant for, and necessary to, all of healthcare,” PDX chief information officer Todd Crosslin said.
Explore Dx is able to offer data transparency and actionable reporting that PDX said is able to offer insight into their business. The HIPAA-compliant platform is powered by the cloud-native data warehouse Snowflake and data visualization and action platform Looker, PDX said, noting that it allows access to data in near real-time. Users can create custom dashboards and reports to help create a data-driven business, the company said.
Camber launches generic Celexa oral solution
Camber Pharmaceuticals has added to its portfolio of oral generics. The Piscataway, N.J.-based company has introduced generic Celexa oral solution (citalopram oral solution, 10 mg/5 ml).
Camber’s generic Celexa oral solution is indicated to treat depression. It will be available in a 240-ml bottle.
Teva launches Qvar RediHaler
Teva has introduced its Qvar RediHaler, a breath-actuated aerosol inhaled corticosteroid that the company said is the first of its kind. The product, which Teva said eliminates the need for hand-breath coordination, is indicated as a maintenance treatment for asthma as a prophylactic therapy in patients ages four years and older.
“Qvar has been an available asthma treatment option for well over a decade, so we are excited by the new technology of Qvar RediHaler that directly addresses an unmet need in the field of asthma management,” Teva executive vice president of North American commercial Brendan O’Grady said. “By merging our breath-actuated inhaler technology with asthma medication, we hope to better serve the needs of the respiratory community and look forward to seeing the adoption of Qvar RediHaler in the coming months.”
The product, which the Food and Drug Administration approved in August 2017, will replace the now-discontinued QVAR. Teva said Qvar RediHaler is designed to be ready to use without priming or shaking and without a spacer or volume-holding chamber. The company said that if desired, the new product will be priced at parity to Qvar.